Get the Stockscreener App
1.925
10.65%
-0.235
Zentalis Pharmaceuticals Inc stock is traded at $1.925, with a volume of 1.07M.
It is down -10.65% in the last 24 hours and down -35.45% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
See More
Previous Close:
$2.16
Open:
$2.17
24h Volume:
1.07M
Relative Volume:
0.57
Market Cap:
$153.93M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.424
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
+10.91%
1M Performance:
-35.45%
6M Performance:
-41.16%
1Y Performance:
-82.92%
1-Day Range:
$1.9207
$2.25
1-Week Range:
$1.61
$2.355
52-Week Range:
$1.61
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.925 | 153.93M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.41 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.93 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.42 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Stock Falling -30.99% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Purchases $103,200.00 in Stock - Armenian Reporter
Zentalis Pharmaceuticals chief legal officer sells $22,643 in stock - MSN
Zentalis pharmaceuticals officer sells $24,590 in stock - MSN
Zentalis Pharmaceuticals executive sells shares worth $4,475 - MSN
Zentalis Pharmaceuticals executive sells shares worth $4,475 By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals Llc Stock: Executives Sell Shares Amid Market Volatility - sharewise
High-Profile Executives Make Bold Moves with Zentalis Pharmaceuticals Stock - TipRanks
Zentalis pharmaceuticals officer sells $24,590 in stock By Investing.com - Investing.com Nigeria
Analysts review Zentalis Pharmaceuticals Inc’s rating - Knox Daily
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Purchases $103,200.00 in Stock - MarketBeat
Zentalis Pharmaceuticals Inc (ZNTL) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) -2.98% Decline Turns Investors Away - Stocks Register
Millennium Management LLC Acquires Significant Stake in Zentalis Pharmaceuticals Inc - GuruFocus.com
Top Executives Show Strong Confidence in Zentalis Pharmaceuticals with Major Stock Buys - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc.ZNTL - Longview News-Journal
Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock By Investing.com - Investing.com Australia
Zentalis pharmaceuticals director Jan Skvarka buys $103,446 in stock - MSN
Zentalis pharmaceuticals director Jan Skvarka buys $103,446 in stock By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals Inc (ZNTL) stock analysis: A comprehensive overview - US Post News
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $6.00 by Analysts at Wells Fargo & Company - MarketBeat
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Zentalis Awards 35,000 Share Options Package in Strategic New Hire Move - StockTitan
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Equities Analysts Set Expectations for ZNTL FY2024 Earnings - Defense World
HC Wainwright Issues Optimistic Forecast for ZNTL Earnings - Defense World
Leerink Partnrs Issues Positive Estimate for ZNTL Earnings - Defense World
Traders Buy High Volume of Call Options on Zentalis Pharmaceuticals (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - MarketBeat
Brokers Issue Forecasts for ZNTL FY2029 Earnings - Defense World
FY2029 Earnings Forecast for ZNTL Issued By HC Wainwright - MarketBeat
Equities Analysts Offer Predictions for ZNTL FY2029 Earnings - MarketBeat
HC Wainwright Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $10.00 - MarketBeat
Zentalis stock price target cut to $10 by H.C. Wainwright - MSN
Wells Fargo & Company Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - Defense World
Zentalis stock plunges to 52-week low of $1.76 amid market challenges - MSN
Jefferies cuts Zentalis stock target to $2.50; maintains hold - MSN
Vanguard Group Inc. Reduces Stake in Zentalis Pharmaceuticals Inc. - GuruFocus.com
UBS Group Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $2.20 - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - Defense World
Zentalis price target lowered to $6 from $8 at Wells Fargo - MSN
Zentalis price target lowered to $10 from $20 at Oppenheimer - Yahoo Finance
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lackner Mark | Chief Scientific Officer |
Feb 03 '25 |
Sale |
1.71 |
14,368 |
24,591 |
512,856 |
| Paul Andrea | Chief Legal Officer |
Feb 03 '25 |
Sale |
1.71 |
13,230 |
22,643 |
1,070,784 |
| Skvarka Jan | Director |
Jan 31 '25 |
Buy |
1.72 |
60,000 |
103,446 |
149,551 |
| Walker Luke Nathaniel | Director |
Jan 31 '25 |
Buy |
1.76 |
14,200 |
24,966 |
86,681 |
| EASTLAND JULIA MARIE | CEO & President |
Jan 31 '25 |
Buy |
1.73 |
28,500 |
49,345 |
28,500 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):